Transporters and drug therapy: Implications for drug disposition and disease

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 3, 2005, Pages 260-277

  Ho, Richard H ^a   Kim, Richard B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; BOSENTAN; CARRIER PROTEIN; CEFALORIDINE; CIDOFOVIR; CIMETIDINE; CLARITHROMYCIN; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; ERYTHROMYCIN; ESTROGEN; FEXOFENADINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOFLOXACIN; LOPERAMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PROBENECID; PROCAINAMIDE; QUINIDINE; RIFAMPICIN; TALINOLOL; TROGLITAZONE; UNINDEXED DRUG; VERAPAMIL; XENOBIOTIC AGENT;

ACTIVE TRANSPORT; ACUTE KIDNEY FAILURE; AMINO ACID TRANSPORT; BLOOD PROTEIN DISORDER; BONE MARROW SUPPRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTASIS; DRUG DISPOSITION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TRANSPORT; DUBIN JOHNSON SYNDROME; EUPHORIA; FAMILIAL HYPOALPHALIPOPROTEINEMIA; GENETIC HETEROGENEITY; HOMEOSTASIS; HUMAN; HYPOLIPOPROTEINEMIA; INTRAHEPATIC CHOLESTASIS; LIVER INJURY; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; TANGIER DISEASE;

ANIMALS; CARRIER PROTEINS; DRUG INTERACTIONS; DRUG THERAPY; HUMANS; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TISSUE DISTRIBUTION; VARIATION (GENETICS);

EID: 24344439264     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.05.011     Document Type: Review

References (147)

1. G. Wilkinson Pharmacokinetics the dynamics of drug absorption, distribution, and elimination J.G. Hardman L.E. Limbird A.G. Gilman Goodman & Gilman's the pharmacological basis of therapeutics 2001 McGraw-Hill New York 3 29
2. E.M. Ross, T.P. Kenakin Pharmacodynamics mechanisms of drug action and the relationship between drug concentration and effect J.G. Hardman L.E. Limbird A.G. Gilman Goodman & Gilman's the pharmacological basis of therapeutics 2001 McGraw-Hill New York 31 43
3. J.C. Venter, M.D. Adams, E.W. Myers, P.W. Li, R.J. Mural, G.G. Sutton The sequence of the human genome Science 291 2001 1304 1351
4. E.S. Lander, L.M. Linton, B. Birren, C. Nusbaum, M.C. Zody, J. Baldwin Initial sequencing and analysis of the human genome Nature 409 2001 860 921
5. B. Hagenbuch, P.J. Meier The superfamily of organic anion transporting polypeptides Biochim Biophys Acta 1609 2003 1 18
6. L.M. Satlin, V. Amin, A.W. Wolkoff Organic anion transporting polypeptide mediates organic anion/HCO3-exchange J Biol Chem 272 1997 26340 26345
7. L. Li, T.K. Lee, P.J. Meier, N. Ballatori Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter J Biol Chem 273 1998 16184 16191
8. B. Gao, B. Stieger, B. Noe, J.M. Fritschy, P.J. Meier Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain J Histochem Cytochem 47 1999 1255 1264
9. L. Li, P.J. Meier, N. Ballatori Oatp2 mediates bidirectional organic solute transport a role for intracellular glutathione Mol Pharmacol 58 2000 335 340
10. A.H. Schinkel, J.J. Smit, O. van Tellingen, J.H. Beijnen, E. Wagenaar, L. van Deemter Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs Cell 77 1994 491 502
11. A. Sparreboom, J. van Asperen, U. Mayer, A.H. Schinkel, J.W. Smit, D.K. Meijer Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine Proc Natl Acad Sci U S A 94 1997 2031 2035
12. A.H. Schinkel, E. Wagenaar, L. van Deemter, C.A. Mol, P. Borst Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A J Clin Invest 96 1995 1698 1705
13. R.B. Kim, M.F. Fromm, C. Wandel, B. Leake, A.J. Wood, D.M. Roden The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors J Clin Invest 101 1998 289 294
14. K.S. Lown, R.R. Mayo, A.B. Leichtman, H.L. Hsiao, D.K. Turgeon, P. Schmiedlin-Ren Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine Clin Pharmacol Ther 62 1997 248 260
15. S. Drescher, H. Glaeser, T. Murdter, M. Hitzl, M. Eichelbaum, M.F. Fromm P-glycoprotein-mediated intestinal and biliary digoxin transport in humans Clin Pharmacol Ther 73 2003 223 231
16. D. Nakai, R. Nakagomi, Y. Furuta, T. Tokui, T. Abe, T. Ikeda Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes J Pharmacol Exp Ther 297 2001 861 867
17. M. Masuda, Y. I'izuka, M. Yamazaki, R. Nishigaki, Y. Kato, K. Ni'inuma Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats Cancer Res 57 1997 3506 3510
18. X.Y. Chu, Y. Kato, Y. Sugiyama Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats Cancer Res 57 1997 1934 1938
19. M. Sasaki, H. Suzuki, K. Ito, T. Abe, Y. Sugiyama Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and multidrug resistance-associated protein 2 (MRP2/ABCC2) J Biol Chem 277 2002 6497 6503
20. G. You Structure, function, and regulation of renal organic anion transporters Med Res Rev 22 2002 602 616
21. G. Lee, S. Dallas, M. Hong, R. Bendayan Drug transporters in the central nervous system brain barriers and brain parenchyma considerations Pharmacol Rev 53 2001 569 596
22. C. Cordon-Cardo, J.P. O'Brien, D. Casals, L. Rittman-Grauer, J.L. Biedler, M.R. Melamed Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites Proc Natl Acad Sci U S A 86 1989 695 698
23. M.F. Fromm, R.B. Kim, C.M. Stein, G.R. Wilkinson, D.M. Roden Inhibition of P-glycoprotein-mediated drug transport a unifying mechanism to explain the interaction between digoxin and quinidine Circulation 99 1999 552 557
24. K. Yokogawa, M. Takahashi, I. Tamai, H. Konishi, M. Nomura, S. Moritani P-glycoprotein-dependent disposition kinetics of tacrolimus studies in mdr1a knockout mice Pharm Res 16 1999 1213 1218
25. C.A. Jankel, L.K. Fitterman Epidemiology of drug-drug interactions as a cause of hospital admissions Drug Saf 9 1993 51 59
26. R.B. Kim, C. Wandel, B. Leake, M. Cvetkovic, M.F. Fromm, P.J. Dempsey Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein Pharm Res 16 1999 408 414
27. C. Handschin, U.A. Meyer Induction of drug metabolism the role of nuclear receptors Pharmacol Rev 55 2003 649 673
28. D.J. Mangelsdorf, R.M. Evans The RXR heterodimers and orphan receptors Cell 83 1995 841 850
29. B. Goodwin, L.B. Moore, C.M. Stoltz, D.D. McKee, S.A. Kliewer Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor Mol Pharmacol 60 2001 427 431
30. B. Goodwin, E. Hodgson, C. Liddle The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module Mol Pharmacol 56 1999 1329 1339
31. H. Wang, S. Faucette, T. Sueyoshi, R. Moore, S. Ferguson, M. Negishi A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression J Biol Chem 278 2003 14146 14152
32. Y. Chen, S.S. Ferguson, M. Negishi, J.A. Goldstein Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor J Pharmacol Exp Ther 308 2004 495 501
33. A. Geick, M. Eichelbaum, O. Burk Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin J Biol Chem 276 2001 14581 14587
34. R.G. Tirona, R.B. Kim Nuclear receptors and drug disposition gene regulation J Pharm Sci 94 2005 1169 1186
35. J.J. Eloranta, G.A. Kullak-Ublick Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism Arch Biochem Biophys 433 2005 397 412
36. H. Wakasugi, I. Yano, T. Ito, T. Hashida, T. Futami, R. Nohara Effect of clarithromycin on renal excretion of digoxin interaction with P-glycoprotein Clin Pharmacol Ther 64 1998 123 128
37. K. Westphal, A. Weinbrenner, T. Giessmann, M. Stuhr, G. Franke, M. Zschiesche Oral bioavailability of digoxin is enhanced by talinolol evidence for involvement of intestinal P-glycoprotein Clin Pharmacol Ther 68 2000 6 12
38. R.A. Boyd, R.H. Stern, B.H. Stewart, X. Wu, E.L. Reyner, E.A. Zegarac Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion J Clin Pharmacol 40 2000 91 98
39. B. Greiner, M. Eichelbaum, P. Fritz, H.P. Kreichgauer, O. von Richter, J. Zundler The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin J Clin Invest 104 1999 147 153
40. A.H. Schinkel, E. Wagenaar, C.A. Mol, L. van Deemter P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs J Clin Invest 97 1996 2517 2524
41. A.J. Sadeque, C. Wandel, H. He, S. Shah, A.J. Wood Increased drug delivery to the brain by P-glycoprotein inhibition Clin Pharmacol Ther 68 2000 231 237
42. R.B. Kim Drugs as P-glycoprotein substrates, inhibitors, and inducers Drug Metab Rev 34 2002 47 54
43. J.M. Burnell, W.M.M. Kirby Effectiveness of a new compound, benemid, in elevating serum penicillin concentrations J Clin Invest 30 1951 697 700
44. S. Jariyawat, T. Sekine, M. Takeda, N. Apiwattanakul, Y. Kanai, S. Sophasan The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1 J Pharmacol Exp Ther 290 1999 672 677
45. A. Ayrton, P. Morgan Role of transport proteins in drug absorption, distribution, and excretion Xenobiotica 31 2001 469 497
46. D.D. Shen, D.L. Azarnoff Clinical pharmacokinetics of methotrexate Clin Pharmacokinet 3 1978 1 13
47. K.S. Basin, A. Escalante, T.D. Beardmore Severe pancytopenia in a patient taking low dose methotrexate and probenecid J Rheumatol 18 1991 609 610
48. N.M. Ellison, R.J. Servi Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU a possible adverse effect due to concomitant indomethacin administration Cancer Treat Rep 69 1985 342 343
49. A. Thyss, G. Milano, J. Kubar, M. Namer, M. Schneider Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen Lancet 1 1986 256 258
50. M. Takeda, S. Khamdang, S. Narikawa, H. Kimura, M. Hosoyamada, S.H. Cha Characterization of methotrexate transport and its drug interactions with human organic anion transporters J Pharmacol Exp Ther 302 2002 666 671
51. J. Lazarou, B.H. Pomeranz, P.N. Corey Incidence of adverse drug reactions in hospitalized patients a meta-analysis of prospective studies JAMA 279 1998 1200 1205
52. J.R. Spivey, S.F. Bronk, G.J. Gores Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calcium J Clin Invest 92 1993 17 24
53. T. Gerloff, B. Stieger, B. Hagenbuch, J. Madon, L. Landmann, J. Roth The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver J Biol Chem 273 1998 10046 10050
54. R.M. Green, F. Hoda, K.L. Ward Molecular cloning and characterization of the murine bile salt export pump Gene 241 2000 117 123
55. B. Stieger, K. Fattinger, J. Madon, G.A. Kullak-Ublick, P.J. Meier Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver Gastroenterology 118 2000 422 430
56. K. Fattinger, C. Funk, M. Pantze, C. Weber, J. Reichen, B. Stieger The endothelin antagonist bosentan inhibits the canalicular bile salt export pump a potential mechanism for hepatic adverse reactions Clin Pharmacol Ther 69 2001 223 231
57. C. Funk, C. Ponelle, G. Scheuermann, M. Pantze Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat Mol Pharmacol 59 2001 627 635
58. E.S. Ho, D.C. Lin, D.B. Mendel, T. Cihlar Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1 J Am Soc Nephrol 11 2000 383 393
59. S.A. Lacy, M.J. Hitchcock, W.A. Lee, P. Tellier, K.C. Cundy Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys Toxicol Sci 44 1998 97 106
60. A.S. Mulato, E.S. Ho, T. Cihlar Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1 J Pharmacol Exp Ther 295 2000 10 15
61. B.M. Tune Nephrotoxicity of beta-lactam antibiotics mechanisms and strategies for prevention Pediatr Nephrol 11 1997 768 772
62. U.A. Meyer Pharmacogenetics and adverse drug reactions Lancet 356 2000 1667 1671
63. N. Kioka, J. Tsubota, Y. Kakehi, T. Komano, M.M. Gottesman, I. Pastan P-glycoprotein gene (MDR1) cDNA from human adrenal normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance Biochem Biophys Res Commun 162 1989 224 231
64. S. Hoffmeyer, O. Burk, O. von Richter, H.P. Arnold, J. Brockmoller, A. Johne Functional polymorphisms of the human multidrug-resistance gene multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci U S A 97 2000 3473 3478
65. M. Siegsmund, U. Brinkmann, E. Schaffeler, G. Weirich, M. Schwab, M. Eichelbaum Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors J Am Soc Nephrol 13 2002 1847 1854
66. M. Drozdzik, M. Bialecka, K. Mysliwiec, K. Honczarenko, J. Stankiewicz, Z. Sych Polymorphism in the P-glycoprotein drug transporter MDR1 gene a possible link between environmental and genetic factors in Parkinson's disease Pharmacogenetics 13 2003 259 263
67. M. Schwab, E. Schaeffeler, C. Marx, M.F. Fromm, B. Kaskas, J. Metzler Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis Gastroenterology 124 2003 26 33
68. A. Siddiqui, R. Kerb, M.E. Weale, U. Brinkmann, A. Smith, D.B. Goldstein Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1 N Engl J Med 348 2003 1442 1448
69. J. Fellay, C. Marzolini, E.R. Meaden, D.J. Back, T. Buclin, J.P. Chave Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1 a pharmacogenetics study Lancet 359 2002 30 36
70. R.G. Tirona, R.B. Kim Pharmacogenomics of organic anion-transporting polypeptides (OATP) Adv Drug Deliv Rev 54 2002 1343 1352
71. T. Sakaeda, T. Nakamura, K. Okumura Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs Pharmacogenomics 4 2003 397 410
72. C. Pauli-Magnus, P.J. Meier Pharmacogenetics of hepatocellular transporters Pharmacogenetics 13 2003 189 198
73. A. Bohan, J.L. Boyer Mechanisms of hepatic transport of drugs implications for cholestatic drug reactions Semin Liver Dis 22 2002 123 136
74. A.C. Lockhart, R.G. Tirona, R.B. Kim Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy Mol Cancer Ther 2 2003 685 698
75. H. Suzuki, Y. Sugiyama Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2) its impact on drug disposition Adv Drug Deliv Rev 54 2002 1311 1331
76. Y. Shu, M.K. Leabman, B. Feng, L.M. Mangravite, C.C. Huang, D. Stryke Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1 Proc Natl Acad Sci U S A 100 2003 5902 5907
77. R. Kerb, U. Brinkmann, N. Chatskaia, D. Gorbunov, V. Gorboulev, E. Mornhinweg Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences Pharmacogenetics 12 2002 591 595
78. R.G. Tirona, B.F. Leake, G. Merino, R.B. Kim Polymorphisms in OATP-C identification of multiple allelic variants associated with altered transport activity among European- and African-Americans J Biol Chem 276 2001 35669 35675
79. Y. Nishizato, I. Ieiri, H. Suzuki, M. Kimura, K. Kawabata, T. Hirota Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes consequences for pravastatin pharmacokinetics Clin Pharmacol Ther 73 2003 554 565
80. T. Nozawa, M. Nakajima, I. Tamai, K. Noda, J. Nezu, Y. Sai Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9) allele frequencies in the Japanese population and functional analysis J Pharmacol Exp Ther 302 2002 804 813
81. S. Toh, M. Wada, T. Uchiumi, A. Inokuchi, Y. Makino, Y. Horie Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome Am J Hum Genet 64 1999 739 746
82. M. Buchler, J. Konig, M. Brom, J. Kartenbeck, H. Spring, T. Horie cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats J Biol Chem 271 1996 15091 15098
83. J. Kartenbeck, U. Leuschner, R. Mayer, D. Keppler Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome Hepatology 23 1996 1061 1066
84. C.C. Paulusma, M. Kool, P.J. Bosma, G.L. Scheffer, F. ter Borg, R.J. Scheper A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome Hepatology 25 1997 1539 1542
85. M. Wada, S. Toh, K. Taniguchi, T. Nakamura, T. Uchiumi, K. Kohno Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome Hum Mol Genet 7 1998 203 207
86. V. Keitel, A.T. Nies, M. Brom, J. Hummel-Eisenbeiss, H. Spring, D. Keppler A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2) Am J Physiol Gastrointest Liver Physiol 284 2003 G165 G174
87. V. Keitel, J. Kartenbeck, A.T. Nies, H. Spring, M. Brom, D. Keppler Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome Hepatology 32 2000 1317 1328
88. K. Hashimoto, T. Uchiumi, T. Konno, T. Ebihara, T. Nakamura, M. Wada Trafficking and functional defects by mutations of the ATP-binding domains in MRP2 in patients with Dubin-Johnson syndrome Hepatology 36 2002 1236 1245
89. R. Mor-Cohen, A. Zivelin, N. Rosenberg, M. Shani, S. Muallem, U. Seligsohn Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome J Biol Chem 276 2001 36923 36930
90. M. Trauner, P.J. Meier, J.L. Boyer Molecular pathogenesis of cholestasis N Engl J Med 339 1998 1217 1227
91. T. Nishida, Z. Gatmaitan, M. Che, I.M. Arias Rat liver canalicular membrane vesicles contain an ATP-dependent bile acid transport system Proc Natl Acad Sci U S A 88 1991 6590 6594
92. P.F. Whitington, K.M. Emerick, F.J. Suchy Familial hepatocellular cholestasis F.J. Suchy R.J. Sokol W.F. Balistreri Liver disease in children 2001 Lippincott, Williams & Wilkins Philadelphia 315 325
93. R. Thompson, S. Strautnieks BSEP function and role in progressive familial intrahepatic cholestasis Semin Liver Dis 21 2001 545 550
94. S.S. Strautnieks, A.F. Kagalwalla, M.S. Tanner, A.S. Knisely, L. Bull, N. Freimer Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24 Am J Hum Genet 61 1997 630 633
95. S.S. Strautnieks, L.N. Bull, A.S. Knisely, S.A. Kocoshis, N. Dahl, H. Arnell A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis Nat Genet 20 1998 233 238
96. J. Noe, B. Stieger, P.J. Meier Functional expression of the canalicular bile salt export pump of human liver Gastroenterology 123 2002 1659 1666
97. J.A. Byrne, S.S. Strautnieks, G. Mieli-Vergani, C.F. Higgins, K.J. Linton, R.J. Thompson The human bile salt export pump characterization of substrate specificity and identification of inhibitors Gastroenterology 123 2002 1649 1658
98. P.L. Jansen, S.S. Strautnieks, E. Jacquemin, M. Hadchouel, E.M. Sokal, G.J. Hooiveld Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis Gastroenterology 117 1999 1370 1379
99. J.F. Deleuze, E. Jacquemin, C. Dubuisson, D. Cresteil, M. Dumont, S. Erlinger Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis Hepatology 23 1996 904 908
100. G. Maggiore, O. Bernard, M. Hadchouel, A. Lemonnier, D. Alagille Diagnostic value of serum gamma-glutamyl transpeptidase activity in liver diseases in children J Pediatr Gastroenterol Nutr 12 1991 21 26
101. J.J. Smit, A.H. Schinkel, R.P. Oude Elferink, A.K. Groen, E. Wagenaar, L. van Deemter Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease Cell 75 1993 451 462
102. J.M. de Vree, E. Jacquemin, E. Sturm, D. Cresteil, P.J. Bosma, J. Aten Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis Proc Natl Acad Sci U S A 95 1998 282 287
103. E. Jacquemin, J.M. de Vree, D. Cresteil, E.M. Sokal, E. Sturm, M. Dumont The wide spectrum of multidrug resistance 3 deficiency from neonatal cholestasis to cirrhosis of adulthood Gastroenterology 120 2001 1448 1458
104. Y. Bacq, T. Sapey, M.C. Brechot, F. Pierre, A. Fignon, F. Dubois Intrahepatic cholestasis of pregnancy a French prospective study Hepatology 26 1997 358 364
105. E. Jacquemin, D. Cresteil, S. Manouvrier, O. Boute, M. Hadchouel Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy Lancet 353 1999 210 211
106. A.J. Smith, A. van Helvoort, G. van Meer, K. Szabo, E. Welker, G. Szakacs MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping J Biol Chem 275 2000 23530 23539
107. J.A. Glomset The plasma lecithins:cholesterol acyltransferase reaction J Lipid Res 9 1968 155 167
108. A. Brooks-Wilson, M. Marcil, S.M. Clee, L.H. Zhang, K. Roomp, M. van Dam Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency Nat Genet 22 1999 336 345
109. M. Bodzioch, E. Orso, J. Klucken, T. Langmann, A. Bottcher, W. Diederich The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease Nat Genet 22 1999 347 351
110. S. Rust, M. Rosier, H. Funke, J. Real, Z. Amoura, J.C. Piette Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1 Nat Genet 22 1999 352 355
111. R.M. Lawn, D.P. Wade, M.R. Garvin, X. Wang, K. Schwartz, J.G. Porter The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway J Clin Invest 104 1999 R25 R31
112. E. Orso, C. Broccardo, W.E. Kaminski, A. Bottcher, G. Liebisch, W. Drobnik Transport of lipids from golgi to plasma membrane is defective in Tangier disease patients and Abc1-deficient mice Nat Genet 24 2000 192 196
113. J. McNeish, R.J. Aiello, D. Guyot, T. Turi, C. Gabel, C. Aldinger High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1 Proc Natl Acad Sci U S A 97 2000 4245 4250
114. C.L. Wellington, E.K. Walker, A. Suarez, A. Kwok, N. Bissada, R. Singaraja ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation Lab Invest 82 2002 273 283
115. N. Wang, D.L. Silver, P. Costet, A.R. Tall Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1 J Biol Chem 275 2000 33053 33058
116. J.F. Oram, R.M. Lawn, M.R. Garvin, D.P. Wade ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages J Biol Chem 275 2000 34508 34511
117. A.E. Bortnick, G.H. Rothblat, G. Stoudt, K.L. Hoppe, L.J. Royer, J. McNeish The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines J Biol Chem 275 2000 28634 28640
118. R.R. Singaraja, L.R. Brunham, H. Visscher, J.J. Kastelein, M.R. Hayden Efflux and atherosclerosis the clinical and biochemical impact of variations in the ABCA1 gene Arterioscler Thromb Vasc Biol 23 2003 1322 1332
119. M.L. Fitzgerald, A.L. Morris, J.S. Rhee, L.P. Andersson, A.J. Mendez, M.W. Freeman Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I J Biol Chem 277 2002 33178 33187
120. A.R. Tanaka, S. Abe-Dohmae, T. Ohnishi, R. Aoki, G. Morinaga, K.I. Okuhira Effects of mutations of ABCA1 in the first extracellular domain on subcellular trafficking and ATP binding/hydrolysis J Biol Chem 278 2002 8815 8819
121. J. Wang, J.R. Burnett, S. Near, K. Young, B. Zinman, A.J. Hanley Common and rare ABCA1 variants affecting plasma HDL cholesterol Arterioscler Thromb Vasc Biol 20 2000 1983 1989
122. S.M. Clee, A.H. Zwinderman, J.C. Engert, K.Y. Zwarts, H.O. Molhuizen, K. Roomp Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease Circulation 103 2001 1198 1205
123. M.E. Brousseau, M. Bodzioch, E.J. Schaefer, A.L. Goldkamp, D. Kielar, M. Probst Common variants in the gene encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and coronary heart disease Atherosclerosis 154 2001 607 611
124. R. Frikke-Schmidt, B.G. Nordestgaard, G.B. Jensen, A. Tybjaerg-Hansen Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population J Clin Invest 114 2004 1343 1353
125. J.C. Cohen, R.S. Kiss, A. Pertsemlidis, Y.L. Marcel, R. McPherson, H.H. Hobbs Multiple rare alleles contribute to low plasma levels of HDL cholesterol Science 305 2004 869 872
126. B. Hagenbuch, P.J. Meier Organic anion transporting polypeptides of the OATP/SLC21 family phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties Pflugers Arch 447 2004 653 665
127. M.J. Dresser, M.K. Leabman, K.M. Giacomini Transporters involved in the elimination of drugs in the kidney organic anion transporters and organic cation transporters J Pharm Sci 90 2001 397 421
128. K.N. Faber, M. Muller, P.L. Jansen Drug transport proteins in the liver Adv Drug Deliv Rev 55 2003 107 124
129. J.D. Allen, A.H. Schinkel Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2) Mol Cancer Ther 1 2002 427 434
130. G.K. Dresser, D.G. Bailey, B.F. Leake, U.I. Schwarz, P.A. Dawson, D.J. Freeman Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine Clin Pharmacol Ther 71 2002 11 20
131. U.I. Schwarz, T. Gramatte, J. Krappweis, A. Berndt, R. Oertel, O. von Richter Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans Clin Pharmacol Ther 65 1999 283 290
132. R.W. Milne, L.A. Larsen, K.L. Jorgensen, J. Bastlund, G.R. Stretch, A.M. Evans Hepatic disposition of fexofenadine influence of the transport inhibitors erythromycin and dibromosulphothalein Pharm Res 17 2000 1511 1515
133. M.A. Hamman, M.A. Bruce, B.D. Haehner-Daniels, S.D. Hall The effect of rifampin administration on the disposition of fexofenadine Clin Pharmacol Ther 69 2001 114 121
134. C. Pauli-Magnus, O. von Richter, O. Burk, A. Ziegler, T. Mettang, M. Eichelbaum Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein J Pharmacol Exp Ther 293 2000 376 382
135. T. Illmer, U.S. Schuler, C. Thiede, U.I. Schwarz, R.B. Kim, S. Gotthard MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients Cancer Res 62 2002 4955 4962
136. K. Jamroziak, W. Mlynarski, E. Balcerczak, M. Mistygacz, J. Trelinska, M. Mirowski Functional C3435T polymorphism of MDR1 gene an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia Eur J Haematol 72 2004 314 321
137. C.R. Yates, W. Zhang, P. Song, S. Li, A.O. Gaber, M. Kotb The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients J Clin Pharmacol 43 2003 555 564
138. K. Kajinami, M.E. Brousseau, J.M. Ordovas, E.J. Schaefer Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner Am J Cardiol 93 2004 1046 1050
139. R.B. Kim, B.F. Leake, E.F. Choo, G.K. Dresser, S.V. Kubba, U.I. Schwarz Identification of functionally variant MDR1 alleles among European Americans and African Americans Clin Pharmacol Ther 70 2001 189 199
140. M.F. Hebert, A.L. Dowling, C. Gierwatowski, Y.S. Lin, K.L. Edwards, C.L. Davis Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors Pharmacogenetics 13 2003 661 674
141. S.R. Brant, C.I. Panhuysen, D. Nicolae, D.M. Reddy, D.K. Bonen, R. Karaliukas MDR1 Ala893 polymorphism is associated with inflammatory bowel disease Am J Hum Genet 73 2003 1282 1292
142. Y. Imai, M. Nakane, K. Kage, S. Tsukahara, E. Ishikawa, T. Tsuruo C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance Mol Cancer Ther 1 2002 611 616
143. A. Sparreboom, H. Gelderblom, S. Marsh, R. Ahluwalia, R. Obach, P. Principe Diflomotecan pharmacokinetics in relation to ABCG2 421C> A genotype Clin Pharmacol Ther 76 2004 38 44
144. M.K. Leabman, C.C. Huang, M. Kawamoto, S.J. Johns, D. Stryke, T.E. Ferrin Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function Pharmacogenetics 12 2002 395 405
145. J. Mwinyi, A. Johne, S. Bauer, I. Roots, T. Gerloff Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics Clin Pharmacol Ther 75 2004 415 421
146. M. Niemi, E. Schaeffeler, T. Lang, M.F. Fromm, M. Neuvonen, C. Kyrklund High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) Pharmacogenetics 14 2004 429 440
147. K. Letschert, D. Keppler, J. Konig Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8) Pharmacogenetics 14 2004 441 452